Given financial considerations, crizotinib is the first choice for most Chinese patients.[16] However, no approved second-line targeted therapies are available once resistance to crizotinib has developed among patients.[17] As a second-generation ALK inhibitor, ceritinib can overcome crizotinib resistance in ALK-positive NSCLC patients, but its efficacy in the treatment of crizotinib-resistant ROS1- rearranged NSCLC patients remains unclear.[13,18]. Here, ROS1 is linked to non-small cell lung carcinoma.